http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
임신성 당뇨병 환자에서 글루코키나제 유전자의 췌도 B 세포 특이 프로모터 -30bp 부위의 변화
김진우(Jin Woo Kim),양인명(In Myung Yang),김성운(Sung Woon Kim),김영설(Young Seol Kim),최영길(Young Kil Choi),우정택(Jung Taek Woo),김세윤(Se Yoon Kim),오승준(Seung Joon Oh),팽정령(Jeon Ryung Paeng),장학철(Hak Chul Chang) 대한내과학회 1999 대한내과학회지 Vol.57 No.5
N/A Glucokinase is expressed only in both liver and pancreatic beta cells and has a key role in the regulation of glucose metabolism in these tissues. A number of gene defects associated with glucokinase gene and the cause of non-insulin-dependent diabetes mellitus are known, and the defects along the -30bp promoter site in particular are thought to be related to diabetes and glucose intolerance. To research on gene study related to diabetes, we looked into the relationship between the variation at -30bp of pancreatic beta cell specific glucokinase gene promoter and gestational diabetes mellitus(GDM) in Korea. Methods : Forty patients with GDM and 62 normal controls were studied. Genomic DNA was extracted from peripheral leukocyte of patients with GDM and normal controls. The nucleotide variation at -30 bp of pancreatic beta cell specific glucokinase gene promoter was analyzed by PCR-SSCP methods. The sequences of amplified DNA were confirmed with direct sequencing method. The clinical features and the response of insulin secretion to oral glucose were analyzed between patients with GDM according to genotypes. Results: Allelic frequency of position -30 bp of pancreatic beta cell specific glucokinase gene promoter did not differ between patients with GDM and normal subjects. However the frequency of G/A and A/A genotypes seemed to show a higher tendency in patients with GDM compare to the normal subjects. Clinical features, insulin response to oral glucose did not differ according to the type of variation at -30bp of pancreatic beta cell specific glucokinase gene promoter. Conclusion : These data suggested that the variation at -30 bp of pancreatic beta cell specific glucokinase gene promoter in patients with GDM are unlikely to be one of the possibilities of the genetic factors in the development of GDM. Therefore more sophisticated studies will be needed to elucidate the role of variation at -30bp of pancreatic beta cell specific glucokinase gene promoter in the insulin secretion to oral glucose. (Korean. J. Med 57:916-924, 1999)
인슐린 비의존성 당뇨병에서 제 4 형 당수송체 유전자의 제한효소분절 길이 다양성
김영설(Young Seol Kim),최성근(Sung Keun Choi),김성운(Sung Woon Kim),양인명(In Myung Yang),김진우(Jin Woo Kim),김광원(Kwang Won Kim),최영길(Young Kil Choi) 대한내과학회 1992 대한내과학회지 Vol.43 No.4
N/A Background: Non-insulin-dependent mellitus (NIDDM) is a heterogenous pathophysiologic disorder with a strong genetic background in the development of disease state and the pathogenesis is characterized by insulin resistance and defective insulin secretion. Regarding to these abnormalities diabetes susceptibility genes may be involved, and one of these candidate genes is the insulin regulatable glucose transporter (GLUT4) expressed predominantly in the skeletal muscle and adipocytes. Recent isolation of genes encoding GLUT4 provides a means to assess the role of possible defect that might contribute to the genetic susceptibility in NIDDM. Methods; We evaluated the RFLP analysis of GLUT4 gene in Korean NIDDM patients with a radioabled GLUT4 cDNA as a probe to define the GLUT4 gene polymorphism as a genetic marker, Results; After digestion with restriction enzyme Kpn I, two band in size 6.5kb and 5.8kb ane noted with polymyphim on 5.8kb. In digestion with Bam HI 25kb and 9kb band. The allele frequency of GLUT 4/Kpn I in NIDDM was lower than that of control (0.29 vs 0.37 P= 0.021). In case of Bam HI the frequency of polymorphic band was not different between NIDDM and control. Conclusion; The GLUT 4 gene RFLP to Kpn I may be considered as a genetic marker of NIDDM in this population. But further studies will be required for its precise nature of gene.
Sheehan 증후군에서 복합뇌하수체 자극검사에 대한 뇌하수체전엽홀몬의 동태
이병기(Byung Ki Lee),신동복(Dong Bok Shin),김성운(Sung Woon Kim),양인명(In Myung Yang),김진우(Jin Woo Kim),김영설(Young Seol Kim),최영길(Young Kil Choi) 대한내과학회 1987 대한내과학회지 Vol.33 No.1
N/A A clinical study on 18 cases of sheehan's syndrome, which were available for combined ptiuitary stimulation test consisting of insulin induced hypoglycemia followed by TRH and LHRH stimulation tests, was made. The results are followings; 1) The age at the time of diagnosis of sheehan's disease was ranged from 28 to 55 and averaged 44 years. The mean duration of appearance of clinical sumptoms after episode of postpartum hemorrhage is 11 years. 2) Basal pituitary function was within normal rage in most patients. 3) The responses of anterior pitutary hormones to combined pituitary stmulation test were impaired more than three in most cases (89%). 4) Panhypopituitarism was observed in only 5 (28%) out of 18 patients. 5) Varying degrees of pituitary response to combined pituitary stimulation test were noted among the various anterior pituitary hormones.
고감도 방사면역측정법에 의한 TSH 측정의 임상적 의의
정영란(Young Ran Jeong),김미나(Mi Na Kim),김성운(Sung Woon Kim),양인명(In Myung Yang),김진우(Jin Woo Kim),김영설(Young Seol Kim),최영길(Young Kil Choi) 대한내과학회 1988 대한내과학회지 Vol.35 No.1
N/A A clinical study was undertaken for the evaluation of the difference and correlation between the determination of TSH by classical RIA and highly sensitive RIA (Immunoradiometric assay; IRMA) and to determine whether the use of IRMA to determine TSH can detect patients without remission earlier than classical RIA. We measured the T3, T4, TSH by RIA, TBII by radioreceptor assay and TSH by IR~MA of 21 control subjects and 27 hyperthyroid patients. Another 5 hyperthyroid patients who had been treated with an antithyroid regimen over 6 months were also analysed by the above parameters after discontinuation of the antithyroid drugs. The results were as follows; 1) TSH concentration measured by IRMA (1.1±0.6μu/ml) was significantly lower than that measured by RIA ~(2.2±0.6μu/ml) and it had a good correlation withthat of RIA (r=0.72, p<0.005). 2) IRMA revealed a good delineation between hyperthyroid patients (0.1±0.09μu/ml) and euthyroid individuals (1.1±0.6μu/ml, p<0.005) 3) IRMA could reveal earlier than RIA that a patient had not been in remission.